Daily Ards Research Analysis
Two new studies inform ARDS-related science from complementary angles. A very large Medicare cohort links concurrent gabapentin and opioid use to increased serious respiratory events (including ARDS), while a preclinical study implicates CCN3/NOV as a pro-inflammatory, pro-apoptotic driver in sepsis-induced lung injury.
Summary
Two new studies inform ARDS-related science from complementary angles. A very large Medicare cohort links concurrent gabapentin and opioid use to increased serious respiratory events (including ARDS), while a preclinical study implicates CCN3/NOV as a pro-inflammatory, pro-apoptotic driver in sepsis-induced lung injury.
Research Themes
- Drug safety and respiratory complications in older adults
- Mechanistic drivers of lung injury/ARDS (CCN3/NOV signaling)
- Translational targets linking inflammation and apoptosis in ALI/ARDS
Selected Articles
1. Adverse respiratory events during treatment with gabapentin and opioids among older adults with spine-related conditions: a propensity-matched cohort study in the US Medicare population.
In a 133,720-patient propensity-matched Medicare cohort with spine-related diagnoses, concurrent gabapentin plus opioid use was associated with a higher risk of composite respiratory events (including ARDS) versus TCA/duloxetine plus opioids (adjusted HR 1.19, 95% CI 1.13–1.25). Pneumonia and respiratory failure were the most frequent events; sensitivity analyses (≤30 days and ≥2 fills) yielded similar results.
Impact: This large, active-comparator, incident-user analysis provides robust pharmacoepidemiologic evidence that gabapentin-opioid co-prescribing may elevate serious respiratory risks in older adults.
Clinical Implications: Exercise caution when co-prescribing gabapentin with opioids in older adults; consider alternatives (e.g., TCA or duloxetine), use the lowest effective gabapentin dose, and monitor closely for pneumonia and respiratory failure.
Key Findings
- Gabapentin+opioids increased composite respiratory events versus active comparators (aHR 1.19; 95% CI 1.13–1.25; p<.0001).
- Pneumonia (3.7% vs 3.0%) and respiratory failure (2.3% vs 1.8%) were the most frequent events.
- Findings were consistent in sensitivity analyses restricted to ≤30 days and requiring ≥2 prescription fills.
Methodological Strengths
- Incident-user, active comparator design with propensity score matching.
- Large national cohort (n=133,720) with predefined composite respiratory outcome.
- Multiple sensitivity analyses confirming robustness.
Limitations
- Observational claims-based design susceptible to residual confounding and misclassification.
- Generalizability limited to older Medicare beneficiaries with spine-related diagnoses.
Future Directions: Replicate in diverse populations; assess dose-response and duration effects; evaluate risk mitigation strategies; explore mechanisms of respiratory compromise with gabapentinoid–opioid combinations.
BACKGROUND CONTEXT: Recent work indicates no increased mortality risk with concurrent gabapentin and opioid use when using an active comparator control design. However, concurrent gabapentin and opioid prescriptions have been associated with greater risk of respiratory depression in some studies. PURPOSE: To compare the risk of respiratory events among Medicare enrollees with histories of spine-related diagnoses treated with gabapentin+opioids versus those treated with tricyclic antidepressants (TCA) or duloxetine+opioids. We hypothesized that enrollees treated with gabapentin+opioids would have increased risk of adverse respiratory events compared to those treated with an active control+opioids. STUDY DESIGN/SETTING: Propensity score-matched cohort study with an incident user, active comparator (TCA/duloxetine) control design. The primary analysis included those who concurrently (within 30 days) filled ≥1 incident gabapentin+≥1 opioid or ≥1 incident TCA/duloxetine+≥1 opioid prescription. PATIENT SAMPLE: US Medicare beneficiaries with histories of spine-related diagnoses 2017 to 2019. People treated with gabapentin+opioids (n=66,860) were matched on demographic and clinical factors to people treated with TCAs/duloxetine+opioids (n=66,860). OUTCOME MEASURES: Time to a composite respiratory outcome consisting of mechanical ventilation, intubation, respiratory failure, pneumonia, or acute respiratory distress syndrome. METHODS: Cox proportional hazard regression was used to estimate adjusted hazard ratios (aHRs) and 95% confidence intervals (95% CIs). RESULTS: Among 133,720 Medicare enrollees (median age 73.3 years; 66.9% female), 6277 (4.7%) experienced respiratory events before the end of follow-up. A total of 3,469 (5.2%) of people who were treated with gabapentin+opioids (median initial dose/day of gabapentin was 300 mg) had respiratory events compared to 2808 (4.2%) of those treated with an active control+opioids. The increased risk in those treated with gabapentin+opioids was statistically significant after adjustment (HR 1.19; 95% CI 1.13, 1.25; p<.0001). The most common respiratory events were pneumonia (3.7% of people in the gabapentin+opioids group versus 3.0% of people in the TCA/duloxetine+opioids group) and respiratory failure (2.3% in the gabapentin+opioids group versus 1.8% in the TCA/duloxetine+opioids group). Results were similar in analyses (a) restricted to ≤30-day follow-up and (b) that required ≥2 fills of each prescription. CONCLUSIONS: While recent work indicates no increased mortality risk with concurrent gabapentin and opioid use in this population, the current findings suggest clinicians should exercise caution in prescribing gabapentin to older adults with spine conditions who are using opioids, due to possible impacts on respiratory events. However, we cannot be certain that unmeasured confounding may explain these results and replication is needed.
2. Nephroblastoma Overexpressed Protein (NOV/CCN3) Elevated Expression of Inflammation Regulators in a Model of Sepsis-Induced Lung Injury.
Using LPS-induced ALI in mice and A549 cells, the authors show that CCN3 (NOV) expression rises with injury and that CCN3 overexpression augments IL-1β and TNFα and promotes epithelial apoptosis (Bax up, Bcl-2 down). Findings position CCN3 as a potential driver and therapeutic target in sepsis-related lung injury.
Impact: Provides mechanistic evidence linking CCN3 to inflammatory amplification and apoptosis in ALI, highlighting a tractable target for ARDS biology.
Clinical Implications: No immediate clinical change; however, CCN3 could serve as a biomarker and future therapeutic target for ARDS. Translational studies should validate CCN3 antagonism in vivo.
Key Findings
- CCN3 expression increases in LPS-induced ALI in vivo and in vitro in a time- and dose-dependent manner.
- CCN3 overexpression elevates IL-1β and TNFα levels (ELISA).
- CCN3 overexpression shifts apoptosis regulators (Bax up, Bcl-2 down) and promotes A549 cell apoptosis.
Methodological Strengths
- Combined in vivo (mouse) and in vitro (A549) models to cross-validate findings.
- Multi-modal assays (ELISA, flow cytometry, Western blot) for mechanistic readouts.
Limitations
- Overexpression approach without complementary loss-of-function or in vivo therapeutic antagonism.
- Limited translational relevance without validation in human samples or clinically relevant models.
Future Directions: Test CCN3 inhibition/knockdown in vivo, delineate downstream signaling pathways, and correlate CCN3 levels with ARDS outcomes in patients.
Nephroblastoma overexpressed protein (NOV, also named CCN3), a member of the CCN (Cy61, CTGF, and NOV) family, is a critical biological marker of the severity of acute respiratory distress syndrome (ARDS). However, no evidence has been presented that CCN3 directly affects acute lung injury (ALI) or ARDS. Intratracheal infusion of LPS is an established method to simulate sepsis and induce ALI. To examine the effect of CCN3 on ALI, we developed in vivo and in vitro models of this disease on mice and type II alveolar epithelial A549 cells, respectively. To further clarify the role of CCN3 in ALI, we constructed a CCN3 overexpression model based on plasmid transfection. The results showed that CCN3 expression was up-regulated in LPS-induced ALI both in vivo and in vitro; this effect was time- and dose-dependent. ELISA revealed that overexpression of CCN3 increased the levels of proinflammatory cytokines IL-1β and TNFα. Flow cytometry and Western blotting showed that overexpression of CCN3 increased the expression of proapoptotic protein Bax and decreased the expression of anti-apoptotic protein Bcl-2, thereby promoting apoptosis of A549 cells. The results suggest that CCN3 antagonists can inhibit progression of inflammation and the development of apoptosis in lung epithelial cells, thereby exerting a possible therapeutic effect in ALI.